As concerns glaucoma, RAS blockade with AT1R blockers achieved IOP reduction in human and monkey glaucoma eyes [24,25] and IOP-independent neuroprotection in rodent glaucoma models [26,27], suggesting a possible etiology of tissue RAS activation and its therapeutic implication in glaucoma [28,29,30]. This evidence concerns the gene AGTR1 and glaucoma.